Inovio Pharmaceuticals, Inc.
INOInovio Pharmaceuticals, Inc. in brief
Inovio Pharmaceuticals, Inc. is a listed company in the Biotechnology industry, based in Plymouth Meeting, Pennsylvania, USA. It was founded in 1979. Its market value was $144 M on 30 October 2026, which makes it the 17,417th largest listed company in the world and the 3,323rd largest in the USA on this site. In the year to December 2025 it had sales of $0 M and a net loss of $85 M. It employs about 317 people and Jacqueline Elizabeth Shea is its chief executive. Its largest business segments by sales in 2025 were Reportable Segments (100%). Its shares trade under the symbol INO (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases. In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate for treating people infected with COVID-19, with more than 170 total vaccine candidates in development (June 2020).
From Wikipedia: read the full article · text available under CC BY-SA 4.0
Inovio Pharmaceuticals, Inc. timeline
- 1983
- 🏁· approximateFounded
- 1999
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2005
- ✎Renamed Inovio Biomedical CorpFormerly Genetronics Biomedical Ltd.
- 2010
- ✎Renamed Inovio Pharmaceuticals, Inc.Formerly Inovio Biomedical Corp.
- 2018
- •Legal Entity Identifier issuedLEI 529900B9W875XDZXTM97 registered.
Events of Inovio Pharmaceuticals, Inc. from Wikidata, SEC EDGAR and the GLEIF LEI register. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #2,841 (Jan 2020) · #1,851 (Jan 2021) · #2,570 (Jan 2022) · #2,911 (Dec 2022) · #3,919 (Jul 2023) · #3,414 (Jan 2024) · #1,896 (Mar 2026) · #3,371 (Aug 2026) · #3,176 (Oct 2026) · #3,327 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- 2060.4×
- Price / book
- 6.0×
- Free cash flow yield
- -61.7%
- Net margin
- -121357.1%
- Operating margin
- -124028.6%
- Return on equity
- -352.5%
- Liabilities / assets
- 67.6%
- Net debt
- $-24M
- Revenue growth
- -68.2%
- R&D / revenue
- 77442.9%
- Revenue per employee
- $0 K
- Profit per employee
- $-268 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $0M | -68.2% | $-87M | $-85M | -121357.1% |
| Dec 2024 | $0M | -73.5% | $-112M | $-107M | -48750.0% |
| Dec 2023 | $1M | -91.9% | $-144M | $-135M | -16279.5% |
| Dec 2022 | $10M | — | $-268M | $-280M | -2727.3% |
| Dec 2021 | — | — | $-301M | $-304M | — |
| Dec 2020 | $7M | +80.3% | $-124M | $-166M | -2245.7% |
| Dec 2019 | $4M | -86.5% | $-111M | $-119M | -2904.1% |
| Dec 2018 | $30M | — | $-94M | $-97M | -318.1% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-89M | $0M | $-89M | $-1.81 | — |
| Dec 2024 | $-104M | $0M | $-105M | $-3.95 | — |
| Dec 2023 | $-124M | $0M | $-125M | $-6.09 | — |
| Dec 2022 | $-216M | $1M | $-217M | $-14.07 | — |
| Dec 2021 | $-216M | $1M | $-217M | $-17.45 | — |
| Dec 2020 | $-178M | $2M | $-180M | $-1.07 | — |
| Dec 2019 | $-98M | $1M | $-99M | $-1.21 | — |
| Dec 2018 | $-74M | $2M | $-76M | $-1.05 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $0M, net income $-49M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 10, 20268-KCurrent reportResults of operations
- Nov 10, 202610-QQuarterly report · period to Sep 2026
- Nov 9, 20268-KCurrent reportMaterial agreement · Regulation FD disclosure · Other events
- Nov 5, 20268-KCurrent reportResults of operations
- Nov 2, 20268-KCurrent reportRegulation FD disclosure · Other events
- Oct 6, 20268-KCurrent reportBylaws amended
- Aug 12, 20268-KCurrent reportResults of operations
- Aug 12, 202610-QQuarterly report · period to Jun 2026
- Jul 31, 20268-KCurrent reportMaterial agreement · Other events
- Jul 29, 20268-KCurrent reportResults of operations
- May 20, 20268-KCurrent reportBylaws amended · Shareholder vote
- May 13, 20268-KCurrent reportResults of operations
Official filings of Inovio Pharmaceuticals, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $0 M
- Operating income
- $-87 M
- Net income
- $-85 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $74 M
- Total liabilities
- $50 M
- Total equity
- $24 M
As of December-2025
Top 100 institutional investors in Inovio Pharmaceuticals, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | FMR LLC | 16,818,985 | +8,364,188 (+98.93%) | 8.98% | $21 M | Nov 10, 2026 |
| 2 | Janus Henderson Group Ltd. | 10,434,210 | — | 5.57% | $13 M | Nov 16, 2026 |
| 3 | Ra Capital Management, L.P. | 7,220,384 | New | 3.85% | $9 M | Nov 16, 2026 |
| 4 | Vanguard Capital Management LLC | 4,599,357 | +948,795 (+25.99%) | 2.46% | $6 M | Nov 13, 2026 |
| 5 | Citadel Advisors LLC | 3,126,541 | +2,884,766 (+1193.16%) | 1.67% | $4 M | Nov 16, 2026 |
| 6 | Two Sigma Investments, LP | 2,539,360 | +1,299,582 (+104.82%) | 1.36% | $3 M | Nov 16, 2026 |
| 7 | D. E. Shaw & Co., Inc. | 2,468,480 | +1,116,824 (+82.63%) | 1.32% | $3 M | Nov 16, 2026 |
| 8 | Marshall Wace, LLP | 2,279,039 | New | 1.22% | $3 M | Nov 13, 2026 |
| 9 | Renaissance Technologies LLC | 1,513,187 | +1,151,848 (+318.77%) | 0.81% | $2 M | Nov 12, 2026 |
| 10 | ADAR1 Capital Management, LLC | 1,444,165 | -699,745 (-32.64%) | 0.77% | $2 M | Nov 16, 2026 |
| 11 | Eversept Partners, LP | 1,381,201 | +345,841 (+33.40%) | 0.74% | $2 M | Nov 16, 2026 |
| 12 | Geode Capital Management, LLC | 1,000,027 | +197,276 (+24.57%) | 0.53% | $1 M | Nov 6, 2026 |
| 13 | Quadrature Capital Ltd | 875,116 | +616,188 (+237.98%) | 0.47% | $1 M | Nov 13, 2026 |
| 14 | BlackRock, Inc. | 763,813 | -15,244 (-1.96%) | 0.41% | $1 M | Nov 13, 2026 |
| 15 | Jane Street Group, LLC | 732,944 | +608,419 (+488.59%) | 0.39% | $1 M | Nov 12, 2026 |
| 16 | Vanguard Fiduciary Trust Co | 622,858 | +142,089 (+29.55%) | 0.33% | $1 M | Nov 13, 2026 |
| 17 | Jacobs Levy Equity Management, Inc | 559,137 | New | 0.30% | $1 M | Nov 16, 2026 |
| 18 | HRT Financial LP | 491,484 | +351,052 (+249.98%) | 0.26% | $1 M | Nov 13, 2026 |
| 19 | UBS Group AG | 383,008 | +120,688 (+46.01%) | 0.20% | $0 M | Nov 10, 2026 |
| 20 | State Street Corp | 354,210 | +17,600 (+5.23%) | 0.19% | $0 M | Nov 12, 2026 |
| 21 | Jpmorgan Chase & Co | 344,964 | +344,918 (+749821.74%) | 0.18% | $0 M | Nov 12, 2026 |
| 22 | XTX Topco Ltd | 329,286 | +223,453 (+211.14%) | 0.18% | $0 M | Nov 16, 2026 |
| 23 | Bank Of America Corp /de/ | 297,355 | New | 0.16% | $0 M | Nov 16, 2026 |
| 24 | Northern Trust Corp | 235,260 | +60,866 (+34.90%) | 0.13% | $0 M | Nov 16, 2026 |
| 25 | Gsa Capital Partners LLP | 151,767 | -113,244 (-42.73%) | 0.08% | $0 M | Nov 16, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Seven Fleet Capital Management LP | 137,100 | New | 0.07% | $0 M | Nov 16, 2026 |
| 27 | DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main | 133,648 | 0 (0.00%) | 0.07% | $0 M | Nov 16, 2026 |
| 28 | GMT Capital Corp | 126,119 | 0 (0.00%) | 0.07% | $0 M | Nov 16, 2026 |
| 29 | Green Alpha Advisors, LLC | 114,857 | +46,802 (+68.77%) | 0.06% | $0 M | Oct 8, 2026 |
| 30 | Goldman Sachs Group Inc | 111,323 | +17,603 (+18.78%) | 0.06% | $0 M | Nov 16, 2026 |
| 31 | Morgan Stanley | 106,112 | +55,856 (+111.14%) | 0.06% | $0 M | Nov 13, 2026 |
| 32 | Millennium Management LLC | 97,963 | -698,144 (-87.69%) | 0.05% | $0 M | Nov 16, 2026 |
| 33 | LexAurum Advisors, LLC | 97,100 | New | 0.05% | $0 M | Oct 19, 2026 |
| 34 | Invesco Ltd. | 94,431 | +14,093 (+17.54%) | 0.05% | $0 M | Nov 12, 2026 |
| 35 | Graham Capital Management, L.P. | 93,305 | New | 0.05% | $0 M | Nov 16, 2026 |
| 36 | Virtu Financial LLC | 93,083 | New | 0.05% | $0 M | Nov 17, 2026 |
| 37 | Greenwich Wealth Management LLC | 88,598 | +56,599 (+176.88%) | 0.05% | $0 M | Nov 12, 2026 |
| 38 | Prime Capital Investment Advisors, LLC | 70,636 | +53,510 (+312.45%) | 0.04% | $0 M | Oct 20, 2026 |
| 39 | Raymond James Financial Inc | 41,412 | -874 (-2.07%) | 0.02% | $0 M | Nov 12, 2026 |
| 40 | Vestmark Advisory Solutions, Inc. | 38,761 | New | 0.02% | $0 M | Nov 16, 2026 |
| 41 | Elevation Point Wealth Partners, LLC | 38,761 | New | 0.02% | $0 M | Nov 5, 2026 |
| 42 | Hudson Bay Capital Management LP | 35,390 | New | 0.02% | $0 M | Nov 13, 2026 |
| 43 | Vanguard Global Advisers, LLC | 30,235 | 0 (0.00%) | 0.02% | $0 M | Nov 13, 2026 |
| 44 | Susquehanna International Group, LLP | 27,502 | New | 0.01% | $0 M | Nov 16, 2026 |
| 45 | Zacks Investment Management | 26,082 | -353 (-1.34%) | 0.01% | $0 M | Nov 16, 2026 |
| 46 | HighTower Advisors, LLC | 26,076 | +13,346 (+104.84%) | 0.01% | $0 M | Nov 10, 2026 |
| 47 | Engineers Gate Manager LP | 23,357 | -10,334 (-30.67%) | 0.01% | $0 M | Nov 16, 2026 |
| 48 | LPL Financial LLC | 23,227 | +6,113 (+35.72%) | 0.01% | $0 M | Nov 6, 2026 |
| 49 | StoneX Group Inc. | 17,134 | +2,882 (+20.22%) | 0.01% | $0 M | Nov 3, 2026 |
| 50 | Qube Research & Technologies Ltd | 13,244 | New | 0.01% | $0 M | Nov 13, 2026 |
| 51 | Wells Fargo & Company/mn | 12,981 | +9,721 (+298.19%) | 0.01% | $0 M | Nov 16, 2026 |
| 52 | BNP Paribas Financial Markets | 12,814 | +12,462 (+3540.34%) | 0.01% | $0 M | Nov 12, 2026 |
| 53 | Mayflower Financial Advisors, LLC | 12,559 | 0 (0.00%) | 0.01% | $0 M | Nov 10, 2026 |
| 54 | Point72 Asset Management, L.P. | 11,868 | New | 0.01% | $0 M | Nov 16, 2026 |
| 55 | SBI Securities Co., Ltd. | 11,328 | +4,514 (+66.25%) | 0.01% | $0 M | Oct 22, 2026 |
| 56 | Signature Estate & Investment Advisors LLC | 11,028 | 0 (0.00%) | 0.01% | $0 M | Oct 13, 2026 |
| 57 | Stephens Inc /ar/ | 10,500 | -5,000 (-32.26%) | 0.01% | $0 M | Nov 12, 2026 |
| 58 | Royal Bank Of Canada | 8,231 | +3,979 (+93.58%) | 0.00% | $0 M | Nov 16, 2026 |
| 59 | Covestor Ltd | 5,120 | 0 (0.00%) | 0.00% | $0 M | Oct 30, 2026 |
| 60 | Simplex Trading, LLC | 3,609 | New | 0.00% | $0 M | Nov 4, 2026 |
| 61 | Barclays PLC | 2,826 | -661 (-18.96%) | 0.00% | $0 M | Nov 6, 2026 |
| 62 | Rockefeller Capital Management L.P. | 2,103 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 63 | Citigroup Inc | 1,502 | New | 0.00% | $0 M | Nov 4, 2026 |
| 64 | Activest Wealth Management | 1,500 | 0 (0.00%) | 0.00% | $0 M | Oct 15, 2026 |
| 65 | Steward Partners Investment Advisory, LLC | 1,281 | -100 (-7.24%) | 0.00% | $0 M | Nov 13, 2026 |
| 66 | BFC Planning, Inc. | 963 | +12 (+1.26%) | 0.00% | $0 M | Nov 13, 2026 |
| 67 | Osaic Holdings, Inc. | 830 | -103 (-11.04%) | 0.00% | $0 M | Nov 12, 2026 |
| 68 | Federation des caisses Desjardins du Quebec | 641 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 69 | Toronto Dominion Bank | 606 | New | 0.00% | $0 M | Nov 16, 2026 |
| 70 | NFSG Corp | 359 | 0 (0.00%) | 0.00% | $0 M | Oct 15, 2026 |
| 71 | Jones Financial Companies Lllp | 316 | +76 (+31.67%) | 0.00% | $0 M | Nov 13, 2026 |
| 72 | PNC Financial Services Group, Inc. | 300 | 0 (0.00%) | 0.00% | $0 M | Nov 6, 2026 |
| 73 | Pioneer Family Office, LLC | 291 | 0 (0.00%) | 0.00% | $0 M | Oct 30, 2026 |
| 74 | Harbour Investments, Inc. | 241 | +4 (+1.69%) | 0.00% | $0 M | Nov 9, 2026 |
| 75 | Root Financial Partners, LLC | 210 | New | 0.00% | $0 M | Oct 21, 2026 |
| 76 | Bolton Securities Corporation | 208 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 77 | Arax Advisory Partners | 203 | +100 (+97.09%) | 0.00% | $0 M | Nov 12, 2026 |
| 78 | Decker Retirement Planning Inc. | 168 | 0 (0.00%) | 0.00% | $0 M | Oct 19, 2026 |
| 79 | Robinhood Markets, Inc. | 120 | — | 0.00% | $0 M | Nov 18, 2026 |
| 80 | Farther Finance Advisors, LLC | 111 | 0 (0.00%) | 0.00% | $0 M | Oct 8, 2026 |
| 81 | Tower Research Capital LLC (TRC) | 104 | -13,197 (-99.22%) | 0.00% | $0 M | Nov 16, 2026 |
| 82 | Northwestern Mutual Wealth Management Co | 83 | +75 (+937.50%) | 0.00% | $0 M | Nov 13, 2026 |
| 83 | Blume Capital Management, Inc. | 83 | 0 (0.00%) | 0.00% | $0 M | Oct 26, 2026 |
| 84 | Smartleaf Asset Management LLC | 83 | 0 (0.00%) | 0.00% | $0 M | Nov 10, 2026 |
| 85 | Rydar Equities, Inc. | 83 | New | 0.00% | $0 M | Oct 13, 2026 |
| 86 | Pittenger & Anderson Inc | 77 | 0 (0.00%) | 0.00% | $0 M | Nov 2, 2026 |
| 87 | National Bank Of Canada /fi/ | 58 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 88 | Mcdonald Partners LLC | 58 | 0 (0.00%) | 0.00% | $0 M | Nov 3, 2026 |
| 89 | Allworth Financial LP | 47 | 0 (0.00%) | 0.00% | $0 M | Nov 17, 2026 |
| 90 | Pinnacle Wealth Planning Services, Inc. | 41 | 0 (0.00%) | 0.00% | $0 M | Oct 27, 2026 |
| 91 | TD Waterhouse Canada Inc. | 41 | -2,342 (-98.28%) | 0.00% | $0 M | Oct 16, 2026 |
| 92 | Nova Financial LLC | 41 | 0 (0.00%) | 0.00% | $0 M | Nov 4, 2026 |
| 93 | Pinnacle Financial Group, Inc. | 39 | — | 0.00% | $0 M | Nov 16, 2026 |
| 94 | Valley National Advisers Inc | 24 | 0 (0.00%) | 0.00% | $0 M | Oct 23, 2026 |
| 95 | Atwood & Palmer Inc | 18 | 0 (0.00%) | 0.00% | $0 M | Oct 8, 2026 |
| 96 | CoreCap Advisors, LLC | 16 | 0 (0.00%) | 0.00% | $0 M | Oct 8, 2026 |
| 97 | Key Financial Inc | 14 | 0 (0.00%) | 0.00% | $0 M | Nov 2, 2026 |
| 98 | Thompson Investment Management, Inc. | 13 | 0 (0.00%) | 0.00% | $0 M | Oct 14, 2026 |
| 99 | Golden State Wealth Management, LLC | 10 | 0 (0.00%) | 0.00% | $0 M | Nov 2, 2026 |
| 100 | Strategic Financial Concepts, LLC | 10 | New | 0.00% | $0 M | Nov 16, 2026 |
Mutual funds holding Inovio Pharmaceuticals, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Fidelity Small Cap Growth FundFidelity Management & Research Company LLC | 6.99 M | $5 M | 3.7% | 0.05% | +24% | Jul 31, 2026 |
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 2.60 M | $3 M | 1.4% | <0.01% | +25% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Growth K6 FundFidelity Management & Research Company LLC | 3.54 M | $2 M | 1.9% | 0.05% | +25% | Jul 31, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 963,325 | $1 M | 0.51% | <0.01% | +30% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Growth FundFidelity Management & Research Company LLC | 1.92 M | $1 M | 1.0% | 0.01% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Small Cap Growth K6 FundFidelity Management & Research Company LLC | 1.00 M | $0 M | 0.54% | 0.01% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 348,001 | $0 M | 0.19% | <0.01% | +1.6% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 280,138 | $0 M | 0.15% | 0.02% | +64% | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 104,005 | $0 M | 0.06% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 96,119 | $0 M | 0.05% | <0.01% | +9.7% | May 31, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 67,976 | $0 M | 0.04% | <0.01% | +150% | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 45,041 | $0 M | 0.02% | <0.01% | −19% | May 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 45,128 | $0 M | 0.02% | <0.01% | +16% | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 42,017 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Tiff Multi-Asset FundTIFF Advisory Services, LLC | 21,590 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 18,882 | $0 M | 0.01% | <0.01% | +60% | Jun 30, 2026 |
| 🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC | 5,208 | $0 M | <0.01% | <0.01% | +417% | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 1,613 | $0 M | <0.01% | <0.01% | +28% | Jun 30, 2026 |
| 🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC | 464 | $0 M | <0.01% | <0.01% | +29% | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 19 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Inovio Pharmaceuticals, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Jacqueline Elizabeth SheaChief Executive Officer, Director | Option exercise | +28,296 | — | — | 123,327 | Form 4 |
| filed | Laurent HumeauChief Scientific Officer | Option exercise | +6,027 | — | — | 48,986 | Form 4 |
| filed | Peter KiesCFO | Option exercise | +8,700 | — | — | 47,542 | Form 4 |
| filed | Michael John SumnerChief Medical Officer | Option exercise | +9,450 | — | — | 44,731 | Form 4 |
| filed | Michael John SumnerChief Medical Officer | Shares withheld for tax | -2,693 | $1.230 | $3 K | 42,038 | Form 4 |
| filed | Jacqueline Elizabeth SheaChief Executive Officer, Director | Shares withheld for tax | -12,306 | $1.230 | $15 K | 111,021 | Form 4 |
| filed | Peter KiesCFO | Shares withheld for tax | -4,688 | $1.230 | $6 K | 42,854 | Form 4 |
| filed | Laurent HumeauChief Scientific Officer | Shares withheld for tax | -2,163 | $1.230 | $3 K | 46,823 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Inovio Pharmaceuticals, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-12 reverse split ; 1-for-4 reverse split
Fails to deliver
- : 10,000 shares at $0.77
- : 1,486 shares at $0.93
- : 1,502 shares at $0.89
- : 450 shares at $0.90
- : 93 shares at $0.84
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Inovio Pharmaceuticals, Inc. scorecard#
Passes 2 of the 13 checks that could be worked out: strongest in financial health (1 of 3), weakest in valuation (0 of 4). Fiscal year 2025; market cap of Oct 30, 2026.
Valuation0 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median6.0×Price to book 6.0× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-61.6%Free cash flow is -61.6% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth1 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-1.81 vs -3.95Diluted EPS -1.81 in fiscal 2025 against -3.95 the year before (report's currency).
- ✓Net income higher than five years earlier-$85 M-$85 M in fiscal 2025 against -$166 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$85 MNet income -$85 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-183.5%-183.5% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities1.4×Current ratio 1.40 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-36.05Z-score -36.05 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year72.6%Diluted shares up 72.6% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Inovio Pharmaceuticals, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 0.1−70.0%100% | 0.2−73.8%100% | 0.8−91.9%100% | 10+478%100% | 1.8−76.1%100% | 7.4+80.2%100% | 4.1−86.5%100% | 30−27.8%100% | 42+19.4%100% | 35—100% | |
| Research and development | 54−28.3%82957% | 76−12.8%34727% | 87−53.8%10418% | 188−24.7%1829% | 249+164%14044% | 94+7.1%1272% | 88−7.6%2141% | 95−3.4%313% | 99+11.1%233% | 89—251% | |
| General and administrative | 33−11.7%50014% | 37−22.2%16990% | 48−47.2%5719% | 90+67.8%879% | 54+44.3%3029% | 37+36.9%503% | 27−7.2%662% | 29+3.6%96.2% | 28+18.4%67.0% | 24—67.6% | |
| Operating expenses | 87−22.8%132971% | 113−22.2%51717% | 145−47.9%17400% | 278−8.3%2707% | 303+130%17072% | 131+14.1%1774% | 115−7.5%2802% | 125−1.0%409% | 126+12.8%298% | 112—316% | |
| Operating income | −87—−132871% | −112—−51617% | −144—−17300% | −268—−2607% | −301—−16972% | −124—−1674% | −111—−2702% | −94—−309% | −84—−198% | −76—−216% | |
| Interest and finance income | 2.4−49.2%3704% | 4.8−41.4%2189% | 8.1—978% | — | — | — | — | — | — | — | |
| Interest expense and finance costs | 0−100%0.0% | 0.2−85.5%81.7% | 1.2−2.5%147% | 1.3−35.2%12.2% | 1.9−77.7%109% | 8.7+9.5%117% | 7.9—193% | 0−100%0.0% | 0.0—0.1% | — | |
| Share of profit of associates | — | — | 0—0.0% | −2.2—−21.1% | −0.4—−24.5% | −4.6—−61.9% | 0—0.0% | 0—0.0% | — | — | |
| Other non-operating income (expense) | −2.6—−4043% | −3.2—−1453% | −4.7—−566% | −3.9−1225%−37.6% | 0.3—19.3% | −0.7−242%−9.5% | 0.5—12.1% | −1.3—−4.4% | −0.2—−0.5% | — | |
| Income before tax | −85—−130000% | −107—−49254% | −135—−16240% | −278—−2706% | −303—−17085% | −163—−2198% | −121—−2938% | −95—−311% | −88—−209% | −74—−208% | |
| Income tax | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | −0.3−112%−6.3% | 2.2—7.1% | 0—0.0% | 0—0.0% | |
| Net income including minority interests | — | — | — | −280—−2727% | −304—−17110% | −167—−2260% | −121—−2932% | −97—−318% | −88—−209% | −74—−208% | |
| Minority interests' share of net income | — | — | — | 0—0.0% | 0—0.0% | −1.1—−14.4% | −1.2—−29.0% | 0—0.0% | 0—0.0% | 0—0.0% | |
| Net income attributable to shareholders | −85—−130000% | −107—−49254% | −135—−16240% | −280—−2727% | −304—−17110% | −166—−2245% | −119—−2903% | −97—−318% | −88—−209% | −74—−208% | |
| Earnings per share, basic | -1.81—— | -3.95—— | -6.09—— | -14.07r-1.17—— | -17.45r-1.45—— | -1.07—— | -1.21—— | -1.05—— | -1.08—— | -1.01—— | |
| Earnings per share, diluted | -1.81—— | -3.95—— | -6.09—— | -14.07r-1.17—— | -17.45r-1.45—— | -1.07—— | -1.21—— | -1.05—— | -1.09—— | -1.01—— | |
| Shares, weighted average (basic) | 47+72.6%— | 27+22.5%— | 22+11.5%— | 20r239+14.3%— | 17r209−88.8%— | 155+57.1%— | 99+6.7%— | 93+13.2%— | 82+11.7%— | 73—— | |
| Shares, weighted average (diluted) | 47+72.6%— | 27+22.5%— | 22+11.5%— | 20r239+14.3%— | 17r209−88.8%— | 155+57.1%— | 99+6.7%— | 93+13.0%— | 82+11.9%— | 73—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 44−32.7%59.6% | 66+360%58.1% | 14−69.1%8.4% | 46−34.9%13.3% | 71−71.6%14.3% | 251+1030%46.5% | 22−6.3%15.4% | 24−0.4%18.1% | 24+24.3%12.7% | 19—11.0% | |
| Short-term investments | 14−49.7%19.2% | 28−78.4%25.0% | 131−36.6%76.6% | 207−37.4%59.3% | 330+105%66.6% | 161+139%29.8% | 67+17.0%46.8% | 58−44.5%43.9% | 104+21.0%55.4% | 86—49.3% | |
| Receivables | 0.0−100.0%0.0% | 1.2−50.1%1.1% | 2.4+41.3%1.4% | 1.7−68.9%0.5% | 5.5−70.5%1.1% | 19+2551%3.4% | 0.7−78.9%0.5% | 3.3−44.8%2.5% | 6.0−62.1%3.2% | 16—9.1% | |
| Other current assets | 2.6−29.7%3.5% | 3.7r2.5−31.4%3.3% | 5.4r5.4−89.2%3.2% | 50+29.1%14.4% | 39−3.8%7.8% | 40+2447%7.5% | 1.6+12.7%1.1% | 1.4−45.9%1.1% | 2.6+48.7%1.4% | 1.7—1.0% | |
| Current assets | 61−37.5%82.3% | 98−36.1%86.4% | 153−51.4%89.6% | 315−29.7%90.4% | 448−4.8%90.4% | 471+400%87.3% | 94+7.3%65.4% | 88−36.5%67.0% | 138+11.0%73.9% | 125—71.7% | |
| Property, plant and equipment | 2.5−30.9%3.4% | 3.7−26.2%3.2% | 5.0−35.8%2.9% | 7.7−55.7%2.2% | 17+53.8%3.5% | 11−11.2%2.1% | 13−19.9%8.9% | 16−12.9%12.2% | 18+103%9.8% | 9.0—5.2% | |
| Right-of-use (leased) assets | 6.5−19.4%8.8% | 8.1−14.5%7.2% | 9.5−7.2%5.6% | 10−11.6%2.9% | 12−9.2%2.3% | 13−7.6%2.4% | 14—9.6% | — | — | — | |
| Goodwill | — | — | 0−100%0.0% | 110.0%3.0% | 110.0%2.1% | 110.0%1.9% | 110.0%7.3% | 110.0%8.0% | 110.0%5.6% | 11—6.1% | |
| Other intangible assets | — | — | 0−100%0.0% | 2.1−18.9%0.6% | 2.6−16.5%0.5% | 3.1−14.8%0.6% | 3.7−22.4%2.6% | 4.8−20.8%3.6% | 6.0−21.2%3.2% | 7.6—4.4% | |
| Investments in associates | — | — | — | — | 0−100%0.0% | 0.4—0.1% | 0—0.0% | — | — | — | |
| Long-term investments | — | — | — | — | — | — | — | 9.4—7.2% | — | — | |
| Total assets | 74−34.4%100% | 113−33.8%100% | 171−51.0%100% | 349−29.7%100% | 496−8.1%100% | 540+275%100% | 144+9.8%100% | 131−30.0%100% | 187+7.8%100% | 174—100% | |
| Accounts payable | — | — | — | 80+67.3%22.9% | 48+125%9.6% | 21+16.3%3.9% | 18−21.2%12.7% | 23−0.6%17.6% | 23+18.8%12.4% | 20—11.3% | |
| Current liabilities | 44+23.6%58.8% | 35−17.0%31.2% | 43−56.1%24.9% | 97+47.3%27.8% | 66+57.6%13.3% | 42+30.4%7.7% | 32−9.4%22.2% | 35−0.3%26.9% | 35−19.2%18.9% | 44—25.2% | |
| Lease liabilities (non-current) | 6.5−30.1%8.8% | 9.4−15.1%8.3% | 11−12.8%6.5% | 13−18.1%3.6% | 15−14.4%3.1% | 18−11.5%3.3% | 20—14.2% | — | — | — | |
| Total liabilities | 50+12.4%67.6% | 45−16.6%39.5% | 54−57.5%31.4% | 126+31.1%36.2% | 96+22.4%19.4% | 79−43.2%14.6% | 139+214%96.2% | 44−1.5%33.6% | 45−11.1%23.9% | 50—29.0% | |
| Retained earnings | −1,815—−2443% | −1,730—−1528% | −1,623—−949% | −1,488—−427% | −1,210—−244% | −906—−168% | −740—−514% | −620—−473% | −523—−280% | −435—−250% | |
| Shareholders' equity | 24−64.8%32.4% | 69−41.6%60.5% | 117−47.2%68.6% | 222−44.4%63.8% | 400−13.3%80.6% | 461+13324%85.4% | 3.4−96.0%2.4% | 87−38.9%66.3% | 142+15.5%76.0% | 123—71.0% | |
| Minority interests | — | — | — | — | — | 0−100%0.0% | 2.0+1946%1.4% | 0.10.0%0.1% | 0.10.0%0.1% | 0.1—0.1% | |
| Total equity | — | — | — | 222−44.4%63.8% | 400−13.3%80.6% | 461+8432%85.4% | 5.4−93.8%3.8% | 87−38.9%66.4% | 142+15.5%76.1% | 123—71.0% | |
| Total liabilities and equity | 74−34.4%100% | 113−33.8%100% | 171−51.0%100% | 349−29.7%100% | 496−8.1%100% | 540+275%100% | 144+9.8%100% | 131−30.0%100% | 187+7.8%100% | 174—100% | |
| Shares outstanding | 69+91.1%— | 36+58.4%— | 23+8.1%— | 21r253−90.3%— | 217+16.3%— | 187+84.3%— | 101+4.3%— | 97+7.6%— | 90+22.0%— | 74—— | |
| Cash-flow statement | |||||||||||
| Share-based compensation | 3.8−43.1%5748% | 6.6−40.4%3029% | 11−50.9%1331% | 23−14.4%220% | 26+68.3%1484% | 16+43.5%211% | 11+2.3%265% | 11−18.5%35.0% | 13+24.7%31.0% | 10—29.6% | |
| Cash from operating activities | −89—−135637% | −104—−47795% | −124—−14948% | −216—−2107% | −216—−12154% | −178—−2401% | −98—−2380% | −74—−241% | −63—−150% | −63—−177% | |
| Capital expenditure | −0.3—−437% | −0.5—−224% | −0.3—−38.6% | −1.0—−9.4% | −1.2—−69.4% | −1.5—−20.5% | −1.0—−24.0% | −2.1—−6.8% | −10—−24.4% | −2.7—−7.7% | |
| Intangible assets bought | — | — | — | — | — | — | — | 0—0.0% | 0—0.0% | −1.2—−3.4% | |
| Cash from investing activities | 14−86.5%21486% | 104+19.1%47793% | 87−20.3%10499% | 110—1068% | −175—−9880% | −59—−793% | −9.0−121%−220% | 42—139% | −28−271%−65.9% | 16—46.0% | |
| Debt issued | — | — | — | — | 0—0.0% | 0−100%0.0% | 97—2370% | 0—0.0% | 0—0.0% | — | |
| Shares issued | 35−3.1%53424% | 36+560%16548% | 5.5−93.4%656% | 83−60.4%808% | 209−53.9%11801% | 454+4900%6132% | 9.1−68.9%221% | 29−69.0%95.9% | 94+1399%223% | 6.3—17.8% | |
| Cash from financing activities | 53+3.1%81187% | 51+931%23639% | 5.0−93.9%600% | 82−61.3%797% | 211−54.5%11917% | 465+341%6278% | 105+240%2563% | 31−67.6%102% | 96+1129%227% | 7.8—22.0% | |
| Exchange-rate effect on cash | 0−100%0.0% | 0.0—14.9% | −0.0—−0.5% | −0.0—−0.2% | −0.0−211%−1.7% | 0.0—0.4% | 0r0.5—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | |
| Change in cash | −22−142%−32964% | 52—23651% | −32—−3848% | −25—−242% | −180−179%−10119% | 229—3084% | −1.5—−36.4% | −0.1−102%−0.3% | 4.7—11.0% | −38—−109% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 0.3+63.9%100% | 0.3—100% | 0—— | 0−100%— | 0*−100%— | 0—— | 0−100%— | 0.1—100% | 0.1*+14.0%100% | 0—— | 0.1—100% | 0—— | 0.1*—100% | |
| Research and development | 46−19.5%15315% | 11−20.4%3552% | 11−25.4%— | 14−12.6%— | 10*−20.4%— | 13−28.8%— | 15−37.1%— | 16−23.1%24625% | 13*−25.3%11014% | 19—— | 23—22916% | 21—— | 17*—16807% | |
| General and administrative | 32−2.9%10739% | 9.2+16.9%3080% | 7.8−8.9%— | 7.9−12.7%— | 7.2*−5.1%— | 7.9−8.6%— | 8.6−16.1%— | 9.0−14.6%13812% | 7.6*−25.8%6497% | 8.6—— | 10—10129% | 11—— | 10*—9979% | |
| Operating expenses | 78−13.4%26054% | 20−6.5%6632% | 19−19.3%— | 22−12.6%— | 17*−14.7%— | 21−22.4%— | 23−30.7%— | 25−20.2%38437% | 20*−25.5%17511% | 27—— | 33—33046% | 31—— | 27*—26786% | |
| Operating income | −78—−25954% | −20—−6532% | −19—— | −22—— | −17*—— | −21—— | −23—— | −25—−38337% | −20*—−17411% | −27—— | −33—−32946% | −31—— | −27*—−26686% | |
| Interest and finance income | 1.6−43.0%538% | 0.4−35.5%119% | 0.4−40.4%— | 0.4−45.6%— | 0.4*−47.3%— | 0.6−50.1%— | 0.6−53.3%— | 0.8−46.1%1237% | 0.9*−53.1%729% | 1.1—— | 1.3—1297% | 1.5—— | 1.8*—1772% | |
| Interest expense and finance costs | — | — | — | — | 0*—— | 0—— | 0—— | 0−100%0.0% | 0*−100%0.0% | 0—— | 0—0.0% | 0.2—— | 0.3*—275% | |
| Share of profit of associates | — | — | — | — | — | — | — | — | — | — | — | — | 0*—0.0% | |
| Other non-operating income (expense) | −5.2—−1749% | −3.2—−1079% | −1.7—— | −0.3—— | 0.0*—— | −1.9—— | −0.7−9388%— | −0.0—−0.7% | −1.9*—−1632% | −0.6—— | 0.0—7.5% | −0.7—— | −0.9*—−839% | |
| Income before tax | — | — | — | — | — | — | — | — | — | — | — | — | −25*—−24358% | |
| Net income attributable to shareholders | −71—−23799% | −49—−16462% | −6.0—— | −20—— | 3.8*—— | −45—— | −24—— | −20—−30140% | −19*—−16566% | −25—— | −32—−31993% | −30—— | −25*—−24358% | |
| Earnings per share, basic | — | -0.50—— | -0.07—— | -0.28—— | — | -0.87—— | -0.61—— | -0.51—— | — | -0.89—— | -1.19—— | -1.31—— | — | |
| Earnings per share, diluted | — | -0.50—— | -0.07—— | -0.28—— | — | -0.87—— | -0.61—— | -0.51—— | — | -0.89—— | -1.19—— | -1.31—— | — | |
| Shares, weighted average (basic) | 99+89.1%— | 99+89.1%— | 82+110%— | 69+79.0%— | — | 52+85.4%— | 39+42.8%— | 39+65.8%— | — | 28—— | 27—— | 23—— | — | |
| Shares, weighted average (diluted) | 99+89.1%— | 99+89.1%— | 82+110%— | 69+79.0%— | — | 52+85.4%— | 39+42.8%— | 39+65.8%— | — | 28—— | 27—— | 23—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 47—78.1% | 47+28.4%78.1% | 32+29.5%63.8% | 26−34.2%52.8% | 44−32.7%59.6% | 37+68.6%52.7% | 24−29.2%35.7% | 40+104%45.7% | 66+360%58.1% | 22—20.3% | 34—25.7% | 20—15.2% | 14—8.4% | |
| Short-term investments | 1.4—2.3% | 1.4−90.2%2.3% | 5.1−77.8%10.4% | 11−59.9%22.9% | 14−49.7%19.2% | 14−77.4%20.5% | 23−69.5%34.0% | 28−66.9%32.6% | 28−78.4%25.0% | 63—59.0% | 76—56.8% | 86—66.6% | 131—76.6% | |
| Receivables | — | — | — | — | 0.0−100.0%0.0% | 1.0−47.5%1.4% | 0.8−52.6%1.2% | 1.3−48.6%1.5% | 1.2−50.1%1.1% | 1.9—1.7% | 1.8—1.3% | 2.6—2.0% | 2.4—1.4% | |
| Other current assets | 3.1—5.1% | 3.1−9.4%5.1% | 3.2−24.8%6.6% | 1.8−20.9%3.5% | 2.6−29.7%3.5% | 3.4−26.4%4.9% | 4.3−19.7%6.3% | 2.2−36.8%2.5% | 3.7r2.5−31.4%3.3% | 4.6—4.3% | 5.4—4.0% | 3.5—2.7% | 5.4r5.4—3.2% | |
| Current assets | 51—85.5% | 51−6.8%85.5% | 40−24.3%80.8% | 39−45.1%79.2% | 61−37.5%82.3% | 55−39.6%79.5% | 53−55.2%77.2% | 72−35.6%82.4% | 98−36.1%86.4% | 91—85.3% | 118—87.9% | 112—86.5% | 153—89.6% | |
| Property, plant and equipment | 1.6—2.6% | 1.6−42.8%2.6% | 1.9−38.9%3.8% | 2.2−34.0%4.4% | 2.5−30.9%3.4% | 2.7−33.0%3.9% | 3.1−31.5%4.5% | 3.3−33.2%3.8% | 3.7−26.2%3.2% | 4.1—3.8% | 4.5—3.4% | 5.0—3.9% | 5.0—2.9% | |
| Right-of-use (leased) assets | 5.2—8.7% | 5.2−25.1%8.7% | 5.7−22.9%11.5% | 6.1−21.0%12.3% | 6.5−19.4%8.8% | 7.0−17.9%10.0% | 7.4−16.6%10.8% | 7.7−15.5%8.9% | 8.1−14.5%7.2% | 8.5—7.9% | 8.8—6.6% | 9.2—7.1% | 9.5—5.6% | |
| Goodwill | — | — | — | — | — | — | — | — | — | — | — | — | 0—0.0% | |
| Other intangible assets | — | — | — | — | — | — | — | — | — | — | — | — | 0—0.0% | |
| Total assets | 60—100% | 60−13.3%100% | 49−27.6%100% | 50−43.0%100% | 74−34.4%100% | 69−35.2%100% | 68−49.0%100% | 87−32.4%100% | 113−33.8%100% | 107—100% | 134—100% | 129—100% | 171—100% | |
| Current liabilities | 89—149% | 89+28.1%149% | 40+25.9%80.8% | 38+38.8%76.2% | 44+23.6%58.8% | 70+197%101% | 32+20.1%46.5% | 27+16.8%31.3% | 35−17.0%31.2% | 23—21.9% | 26—19.7% | 23—18.1% | 43—24.9% | |
| Lease liabilities (non-current) | 4.6—7.6% | 4.6−36.9%7.6% | 5.1−36.2%10.3% | 5.8−33.5%11.6% | 6.5−30.1%8.8% | 7.3−27.3%10.5% | 8.0−24.9%11.7% | 8.7−22.9%10.0% | 9.4−15.1%8.3% | 10—9.4% | 11—8.0% | 11—8.7% | 11—6.5% | |
| Total liabilities | 94—156% | 94+22.0%156% | 45+13.4%91.1% | 44+21.3%87.8% | 50+12.4%67.6% | 77+130%111% | 40+7.2%58.2% | 36+3.9%41.3% | 45−16.6%39.5% | 34—31.3% | 37—27.7% | 35—26.9% | 54—31.4% | |
| Retained earnings | −1,890—−3143% | −1,890—−3143% | −1,841—−3727% | −1,835—−3686% | −1,815—−2443% | −1,819—−2621% | −1,773—−2599% | −1,750—−2005% | −1,730—−1528% | −1,711—−1598% | −1,686—−1260% | −1,653—−1281% | −1,623—−949% | |
| Shareholders' equity | −34—−56.4% | −34—−56.4% | 4.4−84.7%8.9% | 6.1−88.2%12.2% | 24−64.8%32.4% | −7.7−110%−11.1% | 29−70.5%41.8% | 51−45.7%58.7% | 69−41.6%60.5% | 74—68.7% | 97—72.3% | 94—73.1% | 117—68.6% | |
| Total liabilities and equity | 60—100% | 60−13.3%100% | 49−27.6%100% | 50−43.0%100% | 74−34.4%100% | 69−35.2%100% | 68−49.0%100% | 87−32.4%100% | 113−33.8%100% | 107—100% | 134—100% | 129—100% | 171—100% | |
| Shares outstanding | 110—— | 110+106%— | 82+124%— | 70+90.3%— | 69+91.1%— | 54+106%— | 37+41.4%— | 37+56.9%— | 36+58.4%— | 26—— | 26—— | 23—— | 23—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 3.1−28.0%1037% | 0.9*+14.7%290% | 0.8*−7.9%— | 0.7−50.1%— | 0.8*−41.9%— | 0.8*−38.9%— | 0.8*−44.9%— | 1.4−44.6%2142% | 1.3*−41.9%1125% | 1.2*—— | 1.5*—1503% | 2.5—— | 2.3*—2208% | |
| Cash from operating activities | −74—−24852% | −15*—−5110% | −18*—— | −22—— | −19*—— | −22*—— | −21*—— | −27—−41128% | −20*—−16808% | −27*—— | −28*—−27996% | −29—— | −26*—−25597% | |
| Capital expenditure | −0.1—−42.6% | 0*—0.0% | 0*—— | 0—— | −0.1*—— | −0.1*—— | −0.0*—— | −0.1—−90.9% | 0*—0.0% | 0*—— | −0.5*—−449% | −0.0—— | 0*—0.0% | |
| Cash from investing activities | 12−74.5%4165% | 3.7*−58.0%1246% | 6.1*+16.4%— | 2.6—— | −0.1*−100%— | 8.9*−37.0%— | 5.3*−47.0%— | −0.1−100%−79.2% | 35*+73.7%29612% | 14*—— | 10.0*—9891% | 45—— | 20*—19428% | |
| Shares issued | 34+59.0%11364% | 3.0*−58.0%1009% | 3.2*—— | 1.1−1.6%— | 27*+104%— | 7.2*+977%— | 0*−100%— | 1.1−78.9%1687% | 13*+612%11181% | 0.7*—— | 17r17*—16931% | 5.2r5.2—— | 1.8*—1791% | |
| Cash from financing activities | 72+31.2%24166% | 27*+8.3%9029% | 17*—— | 1.0−7.2%— | 27*−6.9%— | 25*+3672%— | −0.0*−100%— | 1.0—1573% | 29*+1485%24912% | 0.7*—— | 33*—32784% | −11—— | 1.8*—1791% | |
| Exchange-rate effect on cash | — | — | — | — | 0*—— | 0*—— | 0*—— | 0−100%0.0% | 0*−100%0.0% | 0*—— | 0*—0.0% | 0.0—— | 0.0*—0.5% | |
| Change in cash | 10−30.1%3478% | 15*+26.4%5164% | 5.3*—— | −18—— | 7.7*−82.5%— | 12*—— | −16*−205%— | −26−589%−39634% | 44*—37716% | −13*—— | 15*—14679% | 5.3—— | −4.5*—−4378% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Inovio Pharmaceuticals, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Business segments
- Reportable Segments$0 M100%-68%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Executive pay at Inovio Pharmaceuticals, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Dr. Shea | $1.6 M | $1.5 M | $872 K | $9 |
| 2024Dr. Shea | $2.1 M | $904 K | $989 K | $10 |
| 2023Dr. Shea | $2.4 M | $1.1 M | $1.2 M | $33 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Inovio Pharmaceuticals, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 1 · Material agreement 8 · Shareholder rights changed 1 · Bylaws or fiscal year changed 2 · Shareholder vote 3 · Results announced 13
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Bylaws or fiscal year changed | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Bylaws or fiscal year changedShareholder vote | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Material agreementShareholder rights changed | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026
Lobbying by Inovio Pharmaceuticals, Inc.#
$30 K spent on lobbying the US Congress and federal agencies in 2024.
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2026 (so far) | $60 K | — | 1 |
| 2024 | $30 K | $30 K | 2 |
| 2023 | $170 K | $170 K | 4 |
| 2022 | $560 K | $560 K | 10 |
| 2021 | $360 K | — | 8 |
| 2020 | $90 K | — | 3 |
| 2019 | $100 K | — | 4 |
| 2018 | $120 K | — | 4 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Inovio Pharmaceuticals”, “INOVIO PHARMACEUTICALS, INC.” and “Inovio Pharmaceuticals, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 | 24 | · | · | · | · | · | 58 | · | · | · | · | · | 82 |
| 2022 | · | · | · | · | · | · | 55 | · | · | · | · | · | 55 |
| 2019 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 58 people (30% of workforce) | Restructuring planSEC 8-K | “(the “ Company ”) committed to and communicated a corporate reorganization plan, including a reduction in force of 58 employees (the “ Reduction ”), representing approximately 30% …” | Filing | |
| 24 people (11% of workforce) | Restructuring planSEC 8-K | “As part of the Reduction, the Company has reduced its overall headcount by approximately 24 employees, which represents 11% of its full-time employees.” | Filing | |
| 55 people (18% of workforce) | Restructuring planSEC 8-K | “As part of the Reduction, the Company has reduced its overall headcount by approximately 55 employees, which represents 18% of its full-time employees.” | Filing | |
| 28% of workforce | Restructuring planSEC 8-K | “In order to reduce operating expenses and conserve cash resources, the Company also announced a reduction of approximately 28% of its workforce and the discontinuation of its immun…” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Inovio Pharmaceuticals, Inc. compares in Biotechnology
- Market cap$144 M · higher than 41% of 726
- Revenue$0 M · higher than 15% of 647
- Revenue growth-68.2% · higher than 11% of 438
- Price / book6.0× · lower than 26% of 534
- FCF yield-61.6% · higher than 20% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Inovio Pharmaceuticals, Inc.🇺🇸 | $144 M | — | — | -68.2% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As on 2021
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, Wikipedia, Wikidata, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Inovio Pharmaceuticals, Inc.? Verify and update this profile — free
Show Inovio Pharmaceuticals, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.